Clinical

Dataset Information

0

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation


ABSTRACT: Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

DISEASE(S): Colorectal Carcinoma,Squamous Cell Carcinoma Of Head And Neck,Pancreatic Adenocarcinoma,Carcinoma,Other Solid Tumors,Non-small Cell Lung Cancer,Colorectal Neoplasms,Head And Neck Squamous Cell Carcinoma,Breast Cancer

PROVIDER: 61464 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2020-07-27 | PXD014754 | Pride
2017-07-03 | PXD006455 | Pride
2016-05-26 | GSE80867 | GEO
2024-03-04 | PXD045000 | Pride
2018-05-18 | GSE114582 | GEO
2023-02-13 | PXD034429 | Pride
2023-02-13 | PXD034539 | Pride
| 2740481 | ecrin-mdr-crc
| PRJEB41094 | ENA
2022-07-21 | GSE186672 | GEO